TY - JOUR AU - Masola, Valentina AU - Carraro, Amedeo AU - Zaza, Gianluigi AU - Bellin, Gloria AU - Montin, Umberto AU - Violi, Paola AU - Lupo, Antonio AU - Tedeschi, Umberto PY - 2015 DA - 2015/09/14 TI - Epithelial to mesenchymal transition in the liver field: the double face of Everolimus in vitro JO - BMC Gastroenterology SP - 118 VL - 15 IS - 1 AB - Everolimus (EVE), a mammalian target of rapamycin inhibitor, has been proposed as liver transplant immunosuppressive drug, gaining wide interest also for the treatment of cancer. Although an appropriate tolerance, it may induce several adverse effects, such as fibro-interstitial pneumonitis due to the acquisition of activated myofibroblasts. The exact molecular mechanism associated with epithelial to mesenchymal transition (EMT) may be crucial also in the liver context. This work examines the role and the molecular mediators of EMT in hepatic stellate cell (HSC) and human liver cancer cells (HepG2) and the potential role of EVE to maintain the epithelial phenotype rather than to act as a potential initiators of EMT. SN - 1471-230X UR - https://doi.org/10.1186/s12876-015-0347-6 DO - 10.1186/s12876-015-0347-6 ID - Masola2015 ER -